Back to overview

Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients.

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Publication date 2011
Author Bortolotti Murielle, Maiolo Elena, Corazza Mattia, Van Dijke Eveline, Schneiter Philippe, Boss Andreas, Carrel Guillaume, Giusti Vittorio, Lê Kim-Anne, Quo Chong Daniel Guae, Buehler Tania, Kreis Roland, Boesch Chris, Tappy Luc,
Project Multi-nuclear magnetic resonance spectroscopy (MRS) and imaging (MRI) on a clinical whole-body MR-system: insulin resistance, ageing, and physical activity
Show all

Original article (peer-reviewed)

Journal Clinical nutrition (Edinburgh, Scotland)
Volume (Issue) 30(4)
Page(s) 494 - 8
Title of proceedings Clinical nutrition (Edinburgh, Scotland)
DOI 10.1016/j.clnu.2011.01.006


BACKGROUND & AIMS High protein diets have been shown to improve hepatic steatosis in rodent models and in high-fat fed humans. We therefore evaluated the effects of a protein supplementation on intrahepatocellular lipids (IHCL), and fasting plasma triglycerides in obese non diabetic women. METHODS Eleven obese women received a 60 g/day whey protein supplement (WPS) for 4-weeks, while otherwise nourished on a spontaneous diet, IHCL concentrations, visceral body fat, total liver volume (MR), fasting total-triglyceride and cholesterol concentrations, glucose tolerance (standard 75 g OGTT), insulin sensitivity (HOMA IS index), creatinine clearance, blood pressure and body composition (bio-impedance analysis) were assessed before and after 4-week WPS. RESULTS IHCL were positively correlated with visceral fat and total liver volume at inclusion. WPS decreased significantly IHCL by 20.8 ± 7.7%, fasting total TG by 15 ± 6.9%, and total cholesterol by 7.3 ± 2.7%. WPS slightly increased fat free mass from 54.8 ± 2.2 kg to 56.7 ± 2.5 kg, p = 0.005). Visceral fat, total liver volume, glucose tolerance, creatinine clearance and insulin sensitivity were not changed. CONCLUSIONS WPS improves hepatic steatosis and plasma lipid profiles in obese non diabetic patients, without adverse effects on glucose tolerance or creatinine clearance. TRIAL NUMBER: NCT00870077,